Weekly 70mg oral alendronate therapy in postmenopausal osteopenic women.

Trial Profile

Weekly 70mg oral alendronate therapy in postmenopausal osteopenic women.

Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Jun 2011

At a glance

  • Drugs Alendronic acid (Primary) ; Calcium; Colecalciferol
  • Indications Metabolic bone diseases; Postmenopausal osteoporosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Jun 2011 Results presented at the 13th World Congress on Menopause.
    • 05 Nov 2010 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top